IPSEN |
Market Closed -
Other stock markets
|
After market 04:00:00 pm | |||
| 122.8 EUR | +0.24% |
|
122.8 | +0.04% |
| 04:06pm | Ipsen Hires New Chief Corporate Affairs Officer | MT |
| 02:55pm | Ipsen: new Chief Corporate Affairs Officer | CF |
Business Summary
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Number of employees: 5,325
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Oncology
75.2
%
| 2,380 | 78.7 % | 2,351 | 75.2 % | -1.19% |
Neurosciences
21.1
%
| 604 | 20.0 % | 659 | 21.1 % | +9.08% |
Rare Diseases
3.7
%
| 41 | 1.4 % | 117 | 3.7 % | +184.43% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Europe
40.2
%
| 1,237 | 40.9 % | 1,257 | 40.2 % | +1.56% |
North America
33.3
%
| 1,032 | 34.1 % | 1,042 | 33.3 % | +0.94% |
Rest of the World
26.5
%
| 756 | 25.0 % | 829 | 26.5 % | +9.73% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 23-05-04 |
| Chief Tech/Sci/R&D Officer | 57 | 23-09-21 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 17-12-31 |
Craig Marks
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 22-02-28 | |
| Corporate Officer/Principal | - | 20-09-30 | |
| Corporate Officer/Principal | 50 | 21-10-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 66 | 15-05-26 |
| Chairman | 66 | 10-11-21 | |
Henri Beaufour
BRD | Director/Board Member | 59 | 05-08-29 |
Antoine Flochel
BRD | Director/Board Member | 59 | 05-08-29 |
Carol Xueref
BRD | Director/Board Member | 67 | 12-05-31 |
Piet Wigerinck
BRD | Director/Board Member | 58 | 18-04-30 |
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director/Board Member | 44 | 20-11-05 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 83,814,526 | 34,829,283 ( 41.56 %) | 1,116,316 ( 1.332 %) | 41.56 % |
Holdings
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Socapharma SAS
| |
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
122.5
EUR
Average target price
126.4
EUR
Spread / Average Target
+3.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.72% | 10.99B | |
| +44.27% | 749B | |
| +38.42% | 605B | |
| -6.40% | 351B | |
| +19.84% | 328B | |
| +8.00% | 292B | |
| +11.72% | 216B | |
| -2.54% | 214B | |
| +2.24% | 167B | |
| +7.53% | 165B |
- Stock Market
- Equities
- IPN Stock
- Company Ipsen
